Gossamer Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 135
- Market Cap
- $206.7M
- Website
- http://www.gossamerbio.com
- Introduction
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
UNITY Biotech appoints new chief medical officer
UNITY Biotechnology appoints Federico Grossi, M.D., Ph.D., as chief medical officer to advance its age-related disease treatments. Grossi's expertise in clinical development and regulatory strategy, especially in ophthalmology, is expected to boost UNITY's therapeutic portfolio, including the Phase 2b ASPIRE study of UBX1325 for diabetic macular edema.
© Copyright 2025. All Rights Reserved by MedPath